Victoria K Brennan1, Simon Dixon. 1. RTI-Health Solutions, Velocity House, Business and Conference Centre, 3 Solly Street, Sheffield, S1 4DE, UK. vbrennan@rti.org
Abstract
OBJECTIVE: This review aimed to identify published studies that provide an empirical measure of process utility, which can be incorporated into estimates of QALY calculations. METHODS: A literature search was conducted in PubMed to identify published studies of process utility. Articles were included if they were written in the English language and reported empirical measures of process utility that could be incorporated into the QALY calculation; those studies reporting utilities that were not anchored on a scale of 0 representing dead and 1 representing full health were excluded from the review. RESULTS: Fifteen studies published between 1996 and 2012 were included. Studies included respondents from the USA, Australia, Scotland and the UK, Europe and Canada. Eight of the included studies explored process utility associated with treatments; six explored process utility associated with screening procedures or tests; and one was performed in preventative care. A variety of approaches were used to detect and measure process utility: four studies used standard gamble techniques; four studies used time trade-off (TTO); one study used conjoint analysis and one used a combination of conjoint analysis and TTO; one study used SF-36 data; one study used both TTO and EQ-5D; and three studies used wait trade-off techniques. Measures of process utility for different drug delivery methods ranged from 0.02 to 0.27. Utility estimates associated with different dosing strategies ranged from 0.005 to 0.09. Estimates for convenience (able to take on an empty stomach) ranged from 0.001 to 0.028. Estimates of process utility associated with screening and testing procedures ranged from 0.0005 to 0.031. Both of these estimates were obtained for management approaches to cervical cancer screening. CONCLUSION: The identification of studies through conventional methods was difficult due to the lack of consistent indexing and terminology across studies; however, the evidence does support the existence of process utility in treatment, screening and preventative care settings. There was considerable variation between estimates. The range of methodological approaches used to identify and measure process utility, coupled with the need for further research into, for example, the application of estimates in economic models, means it is difficult to know whether these differences are a true reflection of the amount of process utility that enters into an individual's utility function, or whether they are associated with features of the studies' methodological design. Without further work, and a standardised approach to the methodology for the detection and measurement of process utility, comparisons between estimates are difficult. This literature review supports the existence of process utility and indicates that, despite the need for further research in the area, it could be an important component of an individual's utility function, which should at least be considered, if not incorporated, into cost-utility analyses.
OBJECTIVE: This review aimed to identify published studies that provide an empirical measure of process utility, which can be incorporated into estimates of QALY calculations. METHODS: A literature search was conducted in PubMed to identify published studies of process utility. Articles were included if they were written in the English language and reported empirical measures of process utility that could be incorporated into the QALY calculation; those studies reporting utilities that were not anchored on a scale of 0 representing dead and 1 representing full health were excluded from the review. RESULTS: Fifteen studies published between 1996 and 2012 were included. Studies included respondents from the USA, Australia, Scotland and the UK, Europe and Canada. Eight of the included studies explored process utility associated with treatments; six explored process utility associated with screening procedures or tests; and one was performed in preventative care. A variety of approaches were used to detect and measure process utility: four studies used standard gamble techniques; four studies used time trade-off (TTO); one study used conjoint analysis and one used a combination of conjoint analysis and TTO; one study used SF-36 data; one study used both TTO and EQ-5D; and three studies used wait trade-off techniques. Measures of process utility for different drug delivery methods ranged from 0.02 to 0.27. Utility estimates associated with different dosing strategies ranged from 0.005 to 0.09. Estimates for convenience (able to take on an empty stomach) ranged from 0.001 to 0.028. Estimates of process utility associated with screening and testing procedures ranged from 0.0005 to 0.031. Both of these estimates were obtained for management approaches to cervical cancer screening. CONCLUSION: The identification of studies through conventional methods was difficult due to the lack of consistent indexing and terminology across studies; however, the evidence does support the existence of process utility in treatment, screening and preventative care settings. There was considerable variation between estimates. The range of methodological approaches used to identify and measure process utility, coupled with the need for further research into, for example, the application of estimates in economic models, means it is difficult to know whether these differences are a true reflection of the amount of process utility that enters into an individual's utility function, or whether they are associated with features of the studies' methodological design. Without further work, and a standardised approach to the methodology for the detection and measurement of process utility, comparisons between estimates are difficult. This literature review supports the existence of process utility and indicates that, despite the need for further research in the area, it could be an important component of an individual's utility function, which should at least be considered, if not incorporated, into cost-utility analyses.
Authors: John Brazier; Ron Akehurst; Alan Brennan; Paul Dolan; Karl Claxton; Chris McCabe; Mark Sculpher; Aki Tsuchyia Journal: Appl Health Econ Health Policy Date: 2005 Impact factor: 2.561
Authors: Kristina S Boye; Louis S Matza; Kimberly N Walter; Kate Van Brunt; Andrew C Palsgrove; Aodan Tynan Journal: Eur J Health Econ Date: 2010-03-12
Authors: Richard H Osborne; Richard De Abreu Lourenço; Andrew Dalton; Jennifer Houltram; David Dowton; Douglas Edgar Joshua; Robert Lindeman; Phoebe Joy Ho Journal: Value Health Date: 2007 Nov-Dec Impact factor: 5.725
Authors: Natalie A Schwehr; Karen M Kuntz; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter; Mary Butler Journal: Drugs Aging Date: 2020-03 Impact factor: 3.923
Authors: Logan Trenaman; Annelies Boonen; Francis Guillemin; Mickael Hiligsmann; Alison Hoens; Carlo Marra; Will Taylor; Jennifer Barton; Peter Tugwell; George Wells; Nick Bansback Journal: J Rheumatol Date: 2017-03-15 Impact factor: 4.666
Authors: George F Sawaya; Erinn Sanstead; Fernando Alarid-Escudero; Karen Smith-McCune; Steven E Gregorich; Michael J Silverberg; Wendy Leyden; Megan J Huchko; Miriam Kuppermann; Shalini Kulasingam Journal: JAMA Intern Med Date: 2019-07-01 Impact factor: 21.873
Authors: David M Meads; John L O'Dwyer; Claire T Hulme; Phani Chintakayala; Karen Vinall-Collier; Michael I Bennett Journal: Patient Date: 2017-10 Impact factor: 3.883